Correction: Aljahili et al. Safety of Switching from a Reference Biologic to Its Biosimilar: A Systematic Review and Meta-Analysis. Biologics 2025, 5, 6

1. Errors in Figure

In the original publication [1], there was a mistake in Figure 1 as published. The data in the Figure is incorrect. “From references (N = 14)” should not be bulleted and should be in alignment with Databases. “Records screened n = 668” should be “Records screened n = 671.” Additionally, “Records excluded n = 939” should be “Records excluded n = 642.” The corrected Figure 1 appears below.

Figure 1. Study Selection.

2. Errors in Table

There were three mistakes in Table 2 in the originally published paper [1]. The corrected Table 2 appears below.

Table 2. Characteristics of included studies.

Authors	Treated Disease	Sample Size (Reference–Reference)	Sample Size (Reference–Biosimilar)	Reference Product	Biosimilar Product	Risk of Bias
Alten et al. [24]	Rheumatoid arthritis	143	143	Infliximab	GP1111	Intermediate
Blauvelt et al. [15]	Psoriasis	127	63	Adalimumab	GP2017	Low quality
Burmester et al. [16]	Rheumatoid arthritis	104	103	Rituximab EU	ABP 798	Intermediate
Cohen et al. [25]	Rheumatoid arthritis	148	146	Adalimumab	BI 695501	Low quality
Feldman et al. [26]	Psoriasis	122	122	Ustekinumab	SB17	High quality
Fleischmann et al. [27]	Rheumatoid arthritis	135	134	Adalimumab	PF-06410293	Intermediate
Hemmer et al. [28]	Multiple sclerosis	103	30	Natalizumab	PB006	High quality
Minckwitz et al. [29]	HER2-positive early breast cancer	171	171	Trastuzumab	ABP 980	High quality
Shim et al. [30]	Rheumatoid arthritis	64	62	Rituximab US	CT-P10	Intermediate
Smolen et al. [31]	Rheumatoid arthritis	101	94	Infliximab	SB2	Low quality
Tony et al. [32]	Rheumatoid arthritis	54	53	Rituximab	GP2013	Intermediate
Ye et al. [33]	Crohn’s disease	54	55	Infliximab	CT-P13	High quality

3. Text Correction

3.1. Changes to Section 3.1. Study Characteristics and Quality Assessment

In the original publication [1], there was an error in the second sentence of the first paragraph in the Results Section. The number 27 should be changed to 29 so the sentence should be “After the initial screening process, 29 studies were deemed eligible for full-text screening, of which 12 studies met the inclusion criteria [15,16,24–33] (Figure 1).”

The second paragraph of the Results section should be corrected to begin with “Of the 12 studies, 3 investigated adalimumab biosimilars, 3 focused on rituximab biosimilars, and 3 evaluated infliximab biosimilars, and one study each assessing natalizumab, ustekinumab and trastuzumab biosimilars. The sample sizes varied significantly, with some studies including 171 participants in each group, while others had fewer than 60 participants in one or both arms.”

3.2. Changes to Section 3.2. Total Adverse Events

The third sentence of the first paragraph should be corrected to “Heterogeneity was reported as I² = 19% (p = 0.248) (Figure 2).”

3.3. Changes to Section 4. Discussion

The second sentence of the fifth paragraph should be corrected to “For instance, a review by Cohen et al. demonstrated a conclusion that switching between biologics and biosimilars did not lead to any significant increase in treatment-related adverse events [17].”

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.